What is the mechanism of action of brigatinib?

Brigatinib is an oral anti-tumor drug. Its mechanism of action is mainly reflected in the inhibition of ALK tyrosine kinase, thereby demonstrating anti-tumor and reducing tumor progression effects.

Brigatinib is a new ALK tyrosine kinase inhibitor. It directly inhibits tumor cell-related signaling pathways by acting on the unique protein kinase structure of ALK fusion-positive lung cancer cells. This inhibitory effect can block the growth and spread of tumor cells, thereby achieving the effect of controlling the disease.

ForALKpositive non-small cell lung cancer (NSCLC), brigatinib shows significant anti-tumor effects. It can induce tumor cell apoptosis, and in clinical trials, up to 83% of patients treated with brigatinib experienced tumor shrinkage, including some cases of complete response.

In addition to its direct anti-tumor effect, brigatinib can also reduce tumor progression and delay the progression of the disease. In the treatment of lung cancer, early use of brigatinib can also play a preventive role, reducing the recurrence and metastasis rates of lung cancer, thereby improving the long-term survival rate of patients.

The mechanism of action of brigatinib is highly specific. It mainly targets lung cancer cells containing the ALK fusion gene. This fusion gene causes abnormal activation of the protein, thereby promoting the growth of malignant tumors. Brigatinib can specifically bind to these abnormal ALK fusion proteins, inhibit their activation, and thereby block the signaling pathway.

Compared with traditional chemotherapy drugs, brigatinib acts on specific cancer cell signaling pathways and has less impact on normal cells, so it is better tolerated clinically. This helps improve patients' quality of life and reduces side effects during treatment.

References:

https://en.wikipedia.org/wiki/Brigatinib